Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Research Article

Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know

H.A. Valand, F. Huda and R.K. Tu
American Journal of Neuroradiology May 2019, 40 (5) 766-768; DOI: https://doi.org/10.3174/ajnr.A6042
H.A. Valand
aFrom the American University of Integrative Sciences (H.A.V.), Brampton, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for H.A. Valand
F. Huda
bDepartment of Radiology (F.H.), George Washington University Hospital, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F. Huda
R.K. Tu
cProgressive Radiology (R.K.T.), George Washington University, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R.K. Tu
  • Article
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

SUMMARY: Chimeric antigen receptor T-cell therapy is an exciting and rapidly emerging “fifth pillar” treatment for hematologic cancers. Unique treatment-related toxicities and cost remain a major hindrance to its widespread application. The commonly faced challenges with this innovative therapy, its neurotoxicity, and manifestation on neuroimaging studies, are reviewed.

ABBREVIATIONS:

CAR
chimeric antigen receptor
CRS
cytokine release syndrome
CRES
CAR-T-cell–related encephalopathy syndrome

What are Chimeric Antigen Receptor T-Cells?

Two major types of immunotherapies have been developed during the past decade; 1) monoclonal antibodies agents specific to target tumor, and 2) adoptive T-cell therapy, agents that mount an immune response against tumor cells. Chimeric antigen receptor (CAR) T-cells are the adoptive T-cell therapy agents that are genetically engineered to produce an immune response against tumor cells.1,2

Who Benefits from CAR T-Cell Therapy?

Since 2017, the US Food and Drug Administration has approved 2 CAR T-cell agents for 3 indications: 1) axicabtagene ciloleucel for relapsed/refractory diffuse large B-cell lymphoma, 2) tisagenlecleucel for pediatric and young adult leukemia, and 3) tisagenlecleucel for adult non-Hodgkin lymphoma. These therapies target, bind, and destroy cluster of differentiation 19 antigen, predominantly found in B-cell tumors.3⇓⇓–6

How Is CAR T-Cell Therapy Delivered to Patients?

Manufacturing of CAR T-cells involves 5 phases: 1) extraction of T-cells with an apheresis technique; 2) reprogramming of T-cells by disarmed virus vectors, which genetically modify T-cells to produce artificial protein receptors called chimeric antigen receptors, used to locate and bind the targeted tumor; 3) expansion and mass production of CAR T-cells and freezing when sufficient numbers are produced; 4) lymphodepletion, a reduction of the white blood cell load, making space for incoming reprogrammed CAR T-cells; and 5) infusion/treatment with CAR T-cells, in which cells multiply and mount an immune response against the targeted cancer cells. According to the current guidelines, patients are required to stay in the hospital from a few days to several weeks depending on their adverse effects profile. Posttreatment recovery time is approximately 2–3 months.7⇓⇓–10

What Are the Major Toxicities of CAR T-Cell Therapy and How Are They Graded?

Cytokine release syndrome (CRS) is the most commonly occurring toxicity in patients receiving CAR T-cell therapy followed by CAR-T-cell–related encephalopathy syndrome (CRES).

CRS results from immune activation resulting in elevated inflammatory cytokines. CRS-associated symptoms can range from fever, malaise, anorexia, and myalgias to end-organ dysfunction. There are 4 grades of CRS toxicity. Grade 1 comprises constitutional symptoms. Grade 2 includes hypotension that responds to fluids or low-dose vasopressors, hypoxia that responds to <40% O2, and grade 2 organ toxicities. Grade 3 encompasses hypotension requiring high-dose vasopressors, hypoxia requiring >40% O2, and grades 3 and 4 organ toxicities. Grade 4 also includes hypoxia requiring mechanical ventilation and grade 4 organ toxicities.11,12 Severe CRS toxicity can rarely progress into fulminant hemophagocytic lymphohistiocytosis.12

CRES-associated symptoms can range from mild neurotoxicity to more severe forms such as seizures, paralysis, raised intracranial pressure (ICP), papilledema, and cerebral edema. CRES is categorized into 4 grades based on neurologic assessment (orientation, naming of objects, ability to write a standard sentence, and counting backwards), raised ICP, and the presence of seizures or motor weakness. Grading of neurologic assessment is as follows: mild (grade 1), moderate (grade 2), severe (grade 3), and critical/obtunded (grade 4). The presence of raised ICP, seizures, or motor weakness comprise grades 3 and 4.13⇓–15

A study conducted by Gofshteyn et al16 concluded that the incidence of neurotoxicity in pediatric and young adult populations (∼45%) is similar to that found in the adult population (∼40%–42%). The study demonstrated that the occurrence of life-threatening neurotoxicity was lower in comparison with adults and all patients had neurologic recovery with no fatal outcomes.

What Are the Neuroradiologic Findings in Patients Receiving CAR T-Cell Therapy?

A study conducted by Davila et al17 at the National Institutes of Health showed that patients who underwent neuroimaging had unremarkable examination findings.

Santomasso et al13 described 2 forms of neurotoxicity: mild and severe. Mild neurotoxicity comprises delirium, tremor, and headaches. Severe neurotoxicity ranges among disorientation, loss of attention, partial-to-global aphasia, myoclonus, and seizures. All patients with mild neurotoxicity had unremarkable MR imaging findings of the brain. In addition, of the 14 patients with severe neurotoxicity, 9 patients also had unremarkable changes. Patients with positive MR imaging findings showed a nonspecific pattern of predominantly white matter involvement extending to the brain stem. These nonspecific changes can also be seen with migraines and chronic microvascular ischemia resulting from common conditions such as hypertension among others.18 Following symptom resolution, 2 of the remaining 5 patients with MR imaging–positive findings had reversal of the MR imaging changes.

What are the Neuroradiologic Recommendations in Patients Receiving CAR T-Cell Therapy?

Given the wide range of nonspecific brain findings and etiologies, the authors suggest a baseline pretreatment MR imaging to document any treatment-related changes. Given their immunocompromised state, these patients are prone to infections, which can result in the release of septic emboli into the bloodstream. This can lead to cerebritis and could further progress to abscess, advocating the use of contrast-enhanced MR imaging.19

What Are the Challenges in Implementing CAR T-Cell Therapy?

Despite its promising treatment response, health plan coverage and drug costs are barriers to access CAR T-cell therapy. Axicabtagene ciloleucel and tisagenlecleucel treatment costs are estimated at $373,000 and $475,000, respectively.20,21 The nondrug costs due to adverse effects, apheresis, and lymphodepletion therapy are not part of these drug regimens and can cost from $30,000 to $56,000.22 In addition, the facility costs to process and produce the final product, along with the use of cell therapy experts are enormous; treatment delivery, risk assessment, and legal counseling teams are important, costly, and essential.23 Currently, CAR T-cell therapy is not approved for Medicare patients. However, recently the US Centers for Medicare and Medicaid Services has proposed comprehensive nationwide coverage for CAR T-cell therapy.24

REFERENCES

  1. 1.↵
    1. Sathyanarayanan V,
    2. Neelapu SS
    . Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol Oncol 2015;9:2043–53 doi:10.1016/j.molonc.2015.10.009 pmid:26548534
    CrossRefPubMed
  2. 2.↵
    1. Khalil DN,
    2. Smith EL,
    3. Brentjens RJ, et al
    . The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016;13:273–90 doi:10.1038/nrclinonc.2016.25 pmid:26977780
    CrossRefPubMed
  3. 3.↵
    1. Ruella M,
    2. Xu J,
    3. Barrett DM, et al
    . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018;24:1499–1503 doi:10.1038/s41591-018-0201-9 pmid:30275568
    CrossRefPubMed
  4. 4.↵
    U.S. Food and Drug Administration. STN: BL 125646/0. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM574106.pdf. Accessed January 30, 2019.
  5. 5.↵
    U.S. Food and Drug Administration. BL 125646/76. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM606523.pdf. Accessed January 28, 2019.
  6. 6.↵
    U.S. Food and Drug Administration. BL 125643/0 https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581259.pdf. Accessed January 28, 2019.
  7. 7.↵
    Chemical & Engineering News. Controlling CAR-T: How scientists plan to make the engineered T cell therapy safer, and work for more cancers. https://cen.acs.org/pharmaceuticals/oncology/Controlling-CAR-T-scientists-plan/96/i19. Accessed February 5, 2019.
  8. 8.↵
    Leukemia and Lymphoma Society. Chimeric Antigen Receptor (CAR) T-Cell Therapy. https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy. Accessed February 6, 2019.
  9. 9.↵
    National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy. Accessed February 6, 2019.
  10. 10.↵
    Dana Farber Cancer Institute. How CAR T-cell works. https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/how-car-t-cell-therapy-works/. Accessed February 6, 2019.
  11. 11.↵
    1. Lee DW,
    2. Gardner R,
    3. Porter DL, et al
    . Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95 doi:10.1182/blood-2014-05-552729 pmid:24876563
    Abstract/FREE Full Text
  12. 12.↵
    1. Neelapu SS,
    2. Tummala S,
    3. Kebriaei P, et al
    . Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62 doi:10.1038/nrclinonc.2017.148 pmid:28925994
    CrossRefPubMed
  13. 13.↵
    1. Santomasso BD,
    2. Park JH,
    3. Salloum D, et al
    . Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018;8:958–71 doi:10.1158/2159-8290.cd-17-1319 pmid:29880584
    Abstract/FREE Full Text
  14. 14.↵
    1. Gust J,
    2. Hay KA,
    3. Hanafi LA, et al
    . Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404–19 doi:10.1158/2159-8290.cd-17-0698 pmid:29025771
    Abstract/FREE Full Text
  15. 15.↵
    MD Anderson Cancer Center. Chimeric Antigen Receptor (CAR) Cell Therapy Toxicity Assessment and Management—Adult. https://www.mdanderson.org/documents/for-physicians/algorithms/clinical-management/clin-management-cytokine-release-web-algorithm.pdf. Accessed February 18, 2019.
  16. 16.↵
    1. Gofshteyn JS,
    2. Shaw PA,
    3. Teachey DT, et al
    . Neurotoxicity after CTL019 in a pediatric and young adult cohort. Ann Neurol 2018;84:537–46 doi:10.1002/ana.25315 pmid:30178481
    CrossRefPubMed
  17. 17.↵
    1. Davila ML,
    2. Riviere I,
    3. Wang X, et al
    . Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25 doi:10.1126/scitranslmed.3008226 pmid:24553386
    Abstract/FREE Full Text
  18. 18.↵
    1. Trauninger A,
    2. Leél-Ossy E,
    3. Kamson DO, et al
    . Risk factors of migraine-related brain white matter hyperintensities: an investigation of 186 patients. J Headache Pain 2011;12:97–103 doi:10.1007/s10194-011-0299-3 pmid:21331756
    CrossRefPubMed
  19. 19.↵
    1. Smirniotopoulos JG,
    2. Murphy FM,
    3. Rushing EJ, et al
    . Patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27:525–51 doi:10.1148/rg.272065155 pmid:17374867
    CrossRefPubMed
  20. 20.↵
    1. Lin JK,
    2. Lerman BJ,
    3. Barnes JI, et al
    . Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol 2018 Sep 13. [Epub ahead of print] doi:10.1200/JCO.2018.79.0642 pmid:30212291
    CrossRefPubMed
  21. 21.↵
    1. Hao Y,
    2. Eldjerou LK,
    3. Yang H, et al
    . Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States. In: Proceedings of the American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia. December 9–12, 2017; abstract 609
  22. 22.↵
    1. Hernandez I,
    2. Prasad V,
    3. Gellad WF
    . Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol 2018;4:994–96 doi:10.1001/jamaoncol.2018.0977 pmid:29710129
    CrossRefPubMed
  23. 23.↵
    Managed Health Care Executive. CAR T-cell therapy life-saving treatment, huge price tag. https://www.managedhealthcareexecutive.com/sites/default/files/legacy/mm/digital/media/mhe1118_ezine_R1.pdf. Accessed February 6, 2019.
  24. 24.↵
    Centers for Medicare & Medicaid Services. Proposed Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N). Last Updated February 15, 2019. https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=291. Accessed February 15, 2019.
  • Received February 17, 2019.
  • Accepted after revision March 6, 2019.
  • © 2019 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 40 (5)
American Journal of Neuroradiology
Vol. 40, Issue 5
1 May 2019
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
H.A. Valand, F. Huda, R.K. Tu
Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know
American Journal of Neuroradiology May 2019, 40 (5) 766-768; DOI: 10.3174/ajnr.A6042

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know
H.A. Valand, F. Huda, R.K. Tu
American Journal of Neuroradiology May 2019, 40 (5) 766-768; DOI: 10.3174/ajnr.A6042
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • What are Chimeric Antigen Receptor T-Cells?
    • Who Benefits from CAR T-Cell Therapy?
    • How Is CAR T-Cell Therapy Delivered to Patients?
    • What Are the Major Toxicities of CAR T-Cell Therapy and How Are They Graded?
    • What Are the Neuroradiologic Findings in Patients Receiving CAR T-Cell Therapy?
    • What are the Neuroradiologic Recommendations in Patients Receiving CAR T-Cell Therapy?
    • What Are the Challenges in Implementing CAR T-Cell Therapy?
    • REFERENCES
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Use of Transcranial Doppler as a Biomarker of CAR T Cell-Related Neurotoxicity
  • Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity
  • Chimeric Antigen Receptor T-Cell Therapy: Are Neuroradiologists Prepared?
  • Crossref (13)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report
    Kai Rejeski, Wolfgang G. Kunz, Martina Rudelius, Veit Bücklein, Viktoria Blumenberg, Christian Schmidt, Philipp Karschnia, Florian Schöberl, Konstantin Dimitriadis, Louisa von Baumgarten, Joachim Stemmler, Oliver Weigert, Martin Dreyling, Michael von Bergwelt-Baildon, Marion Subklewe
    BMC Infectious Diseases 2021 21 1
  • Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
    Xiang Zhou, Leo Rasche, K. Martin Kortüm, Sophia Danhof, Michael Hudecek, Hermann Einsele
    Frontiers in Immunology 2020 11
  • Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity
    Elisaveta Sokolov, Philipp Karschnia, Reuben Benjamin, Robert D M Hadden, Robert C D Elwes, Lee Drummond, Devyani Amin, Vitor Paiva, Alex Pennisi, Aline Herlopian, Matthew Frigault, Robin Sanderson, Shafqat Inam, Andrew J Cole, Jorg Dietrich
    BMJ Neurology Open 2020 2 1
  • Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists
    Patricia M. de Groot, Octavio Arevalo, Komal Shah, Chad D. Strange, Girish S. Shroff, Jitesh Ahuja, Mylene T. Truong, John F. de Groot, Ioannis Vlahos
    RadioGraphics 2022 42 1
  • The Facial Nerve: Anatomy and Pathology
    Ana Carolina Ottaiano, Gustavo Dalul Gomez, Tomás de Andrade Lourenção Freddi
    Seminars in Ultrasound, CT and MRI 2023 44 2
  • Imaging the Side Effects of CAR T Cell Therapy: A Primer for the Practicing Radiologist
    Sophia Huang, Dorine de Jong, Jeeban P. Das, Reginald Scott Widemon, Brian Braumuller, Jacienta Paily, Aileen Deng, Connie Liou, Tina Roa, Alice Huang, Hong Ma, Belinda D’Souza, Jay Leb, Jade L’Hereaux, Pamela Nguyen, Lyndon Luk, Mark Francescone, Randy Yeh, Valerie Maccarrone, Laurent Dercle, Mary M. Salvatore, Kathleen M. Capaccione
    Academic Radiology 2023 30 11
  • Non-Hodgkin Lymphoma Imaging Spectrum in Children, Adolescents, and Young Adults
    Eman Marie, María Navallas, Douglas S. Katz, Elnaz Farajirad, Angela Punnett, Sunit Davda, Amer Shammas, Kamaldine Oudjhane, Reza Vali
    RadioGraphics 2022 42 4
  • Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma
    Daanish Hoda, Robert Richards, Edward A Faber, Abhinav Deol, Bradley D Hunter, Elizabeth Weber, Heather DiFilippo, Toni Henderson-Clark, Linda Meaux, Concetta Crivera, Carrie Riccobono, Ashraf Garrett, Carolyn C Jackson, Jessica Fowler, Panteli Theocharous, Raj Stewart, Andrea L Lorden, David L Porter, Ariel Berger
    Future Oncology 2022 18 19
  • Use of Transcranial Doppler as a Biomarker of CAR T Cell–Related Neurotoxicity
    Kathryn B. Holroyd, Daniel B. Rubin, Sarah LaRose, Andrew Monk, Sarah Nikiforow, Caron Jacobson, Henrikas Vaitkevicius
    Neurology Clinical Practice 2022 12 1
  • Chimeric Antigen Receptor T-Cell Therapy: Are Neuroradiologists Prepared?
    S.A. Nabavizadeh
    American Journal of Neuroradiology 2019

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire